Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
-
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
Industry experts launch a free Ebook to help first-time biotech CEOs navigate funding, strategy, partnerships and the decisions that define success.
-
Strategic win of European chemicals leader fuels record growth in Kneat's new customer additions for 2025
-
EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic Trial Initiation Marks EvolveImmune’s Transition to Clinical-Stage...
-
Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.
-
In the registrational clinical trial, zurletrectinib demonstrated outstanding efficacy and a favorable safety profile, with ORR of 89.1% and DCR of 96.4%.
-
Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including MZL, MCL, CLL/SLL, PCNSL and DLBCL.
-
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system,...